slider-main.png

Ovoca Bio plc’s goal is to bring value to its Shareholders through selective investment in pharmaceutical and biotechnology development opportunities. 
In 2018 Ovoca Bio made its first investment in Ivix Ltd with its highly promising clinical stage asset. Ivix Ltd is developing a new proprietary drug for female sexual dysfunction, an area of significant unmet medical need. The magnitude of demand for treatments for female sexual dysfunction has only recently been recognized; it has the potential to become a substantial pharmaceutical market. At present, there are only a few options available for treating female sexual dysfunction, all with significant shortcomings. The observed efficacy and safety profile of Ivix’ drug candidate suggests it is capable of becoming a market leader in this therapeutic area. 

IVIX_banner.png

News

May 31, 2019

Ovoca Presents at BIO 2019 International Convention, Philadelphia

More...
May 7, 2019

Ovoca Bio plc is pleased to announce that on 1st March 2019 its subsidiary, IVIX, was granted patent No 234753 in Israel covering any use for a large list of peptide variants based on BP-101.

More...
April 23, 2019

Ovoca Bio plc is pleased to announce that its subsidiary IVIX has commenced the process of preparing an integrated Clinical Development Plan (“CDP”) for its investigational drug candidate, Libicore (BP-101), for both the US and EU regions with Biorasi LLC (“Biorasi”), an experienced US-based contract research organization.

More...